Research feed 
Overview 
Microbiome Signature 
Interventions 
FAQs 
Research Feed 
Update History 
References 2025-08-04 13:36:57
Ovarian Cancer majorpublished
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Ovarian Cancer
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read MoreI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
-
Divine Aleru
Read More
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
Overview
Ovarian cancer (OC) remains one of the most deadly cancers affecting women, with an estimated 320,000 new cases diagnosed worldwide annually, making it the eighth most commonly diagnosed cancer. It also accounts for over 200,000 deaths each year, reflecting its high lethality. The disease is often diagnosed at advanced stages (stage III and IV) due to the lack of early symptoms, leading to a poor prognosis.[1][2] Around 70% of ovarian cancer cases are diagnosed in these late stages, significantly reducing survival rates. The five-year survival rate for ovarian cancer remains dismally low, with an average of 30-45% in most countries.[3] This poor prognosis is largely attributed to the late detection of the disease and the frequent development of chemoresistance, particularly to platinum-based chemotherapy, the standard treatment for ovarian cancer.[4] Ovarian cancer is characterized by high heterogeneity, with various histological subtypes and molecular profiles. The most common type, epithelial ovarian cancer (EOC), makes up approximately 90% of all ovarian cancer cases.[5] Emerging research has shown the critical role of the microbiome in ovarian cancer progression, with recent studies linking both the vaginal and gut microbiota to carcinogenesis. Dysbiosis, or microbial imbalance, in these areas may contribute to inflammation, immune evasion, and tumor progression.[6] The gut microbiome, in particular, is known to influence the immune system and metabolic pathways, potentially playing a significant role in the development of ovarian cancer.[7] Repurposed non-oncology drugs are showing promise in ovarian cancer treatment.[8] These drugs have demonstrated antiproliferative, pro-apoptotic, and antimetastatic properties, offering a more accessible and cost-effective alternative to traditional chemotherapy.
Associated Conditions
Ovarian cancer is closely associated with several gynecological and systemic conditions that increase the risk of developing the disease. One of the most notable associations is with endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, often on the ovaries.[9] Women with endometriosis face a significantly increased risk of developing ovarian cancer.[10] Studies show that the relative risk of ovarian cancer in women with endometriosis can be as high as 4.2 times compared to the general population.[11] Specifically, women with ovarian endometriosis have a higher likelihood of developing endometrioid and clear cell subtypes of ovarian cancer. Other significant risk factors for ovarian cancer include genetic mutations, particularly in the BRCA1 and BRCA2 genes.[12] Women carrying mutations in these genes are at a substantially higher risk, with up to 15% of ovarian cancers being attributed to inherited genetic mutations.[13] These mutations lead to an increased risk of both ovarian and breast cancers, with the lifetime risk of developing ovarian cancer for BRCA1 carriers reaching 40-60%, and for BRCA2 carriers, the risk is about 10-30%.[14] Obesity and hormonal therapies, including the use of hormone replacement therapy (HRT), are additional risk factors for ovarian cancer. Studies suggest that obesity increases the risk of ovarian cancer due to chronic inflammation and the impact of adiposity on hormonal pathways. Women using HRT, especially after menopause, may experience an elevated risk of developing ovarian cancer due to prolonged exposure to estrogen.
Causes
The causes of ovarian cancer are complex and multifactorial, involving genetic, hormonal, and environmental factors. A major hypothesis for ovarian cancer initiation is hormonal exposure, particularly to estrogen. Extended exposure to estrogen, through factors like early menarche, late menopause, and the use of oral contraceptives or HRT, can increase the risk of ovarian cancer.[15][16] Ovulation frequency has also been implicated in ovarian cancer development, as frequent ovulation increases the number of times the ovarian surface epithelium is damaged, leading to an accumulation of genetic mutations.[17] Genetic mutations, particularly in BRCA1 and BRCA2, are well-established causes of ovarian cancer.[18] These genes are involved in DNA repair mechanisms, and mutations in them lead to genomic instability, increasing the risk of cancer development. Lynch syndrome, caused by mutations in MLH1, MSH2, and other mismatch repair genes, is another hereditary condition that predisposes individuals to ovarian cancer.
Emerging theories suggest that microbiome dysbiosis may also play a pivotal role in ovarian cancer pathogenesis. The vaginal and gut microbiota have been shown to influence immune responses and metabolic pathways that can either promote or inhibit cancer development. Dysbiosis in the vaginal microbiota, characterized by a depletion of Lactobacillus and an increase in anaerobic bacteria, has been associated with higher rates of ovarian cancer.[19][20] Several case–control studies have identified that prior sexually transmitted infection, particularly Chlamydia trachomatis, increases ovarian cancer risk.[21] It is hypothesized that pelvic infections may contribute to ovarian carcinogenesis by inducing DNA damage, oxidative stress, and pro-inflammatory responses.[22] This link is still under exploration, but the growing body of evidence suggests that microbiota-related factors may contribute significantly to the disease’s onset and progression.
| Causal Theory | Evidence |
|---|---|
| Hormonal Exposure (Estrogen) | Increased estrogen exposure is linked to higher ovarian cancer risk. Studies have shown that prolonged exposure to estrogen, particularly in the form of menopausal hormone therapy, can increase the risk of developing ovarian cancer. [23] |
| Genetic Mutations (BRCA1/2) | Mutations in BRCA1/2 are linked to a significant increase in ovarian cancer risk.[24] |
| Microbiome Dysbiosis | Vaginal and gut microbial imbalances contribute to ovarian cancer risk.[25] |
Diagnosis
Diagnosing ovarian cancer remains one of the greatest challenges in oncology due to its often silent progression and the lack of effective screening tools. Currently, serum biomarkers like CA125, HE4, and CEA are used in diagnosis, but these markers lack the sensitivity and specificity required for early-stage detection.[26][27] CA125, for instance, is elevated in only about 50-60% of early-stage cases.[28][29] Imaging techniques like ultrasound and CT scans are often used to detect masses in the ovaries, but they cannot reliably distinguish between benign and malignant growths. In recent years, liquid biopsy has shown promise as a non-invasive diagnostic method.[30] Additionally, the role of the microbiome in ovarian cancer diagnosis is being increasingly recognized. Studies have demonstrated that microbiome signatures, particularly from vaginal and gut microbiota, could serve as potential diagnostic biomarkers, offering a new avenue for early detection.[31] This approach may lead to the development of microbiome-based diagnostic tests, allowing for less invasive, earlier detection of ovarian cancer.
Primer
Ovarian cancer is one of the deadliest gynecological cancers, primarily due to its late-stage diagnosis and asymptomatic nature. The disease often presents with vague symptoms, leading to diagnoses at advanced stages with a low survival rate. High-grade serous ovarian cancer (HGSOC), the most common and aggressive subtype, shows significant metabolic and genetic dysregulation. Recent research highlights the crucial role of the microbiome, particularly vaginal and gut microbiota, in cancer progression and treatment responses. Metabolomics, the study of metabolites in biological samples, has identified biomarkers related to OC, including altered glycolysis and lipid synthesis, which are hallmarks of cancer cell survival and proliferation. Additionally, metallomics, which examines the role of metals like zinc, copper, cadmium, lead, and chromium, has underscored their involvement in cancer progression.[32] Dysregulation of essential metals, along with toxic metals like cadmium and lead, can cause DNA damage, oxidative stress, and hormonal disruption, contributing to tumor growth and chemoresistance. Understanding the intersections between the microbiome, metallomics, and metabolic alterations is key to improving early detection and treatment strategies for ovarian cancer.
Metallomic Signatures
Heavy metals like zinc, copper, lead, cadmium, and chromium are essential for various biological functions, but their dysregulation can promote tumorigenesis. These metals participate in key cellular processes such as oxidative stress, DNA repair, and apoptosis. Elevated levels of toxic metals, such as cadmium and lead, have been linked to ovarian cancer progression through genotoxicity, oxidative stress, and disruption of estrogen signaling.
What are the Metallomic Signatures of Ovarian Cancer
Zinc
Zinc (Zn) is an essential trace metal that plays a pivotal role in various biological processes, including DNA synthesis, cell division, and immune function. In ovarian cancer, zinc levels in blood and tissues have been correlated with the disease’s prognosis. In a study, it was observed that higher concentrations of zinc are associated with longer recurrence-free survival in ovarian cancer patients.[33] This association indicates that zinc may have a protective effect against the recurrence of ovarian cancer. Zinc’s involvement in cell cycle regulation and apoptosis makes it an important factor in cancer cell proliferation and survival. However, its dysregulation can contribute to cancer progression by promoting an oxidative environment that damages cellular components, including DNA.[34]
Copper
Copper (Cu) is another essential metal that plays a role in several enzymatic reactions, including those involved in angiogenesis and cell proliferation.[35] In ovarian cancer, copper levels are often found to be elevated in both serum and tumor tissues. Increased levels of copper in the blood of patients resulted in a longer duration of recurrence-free survival, indicating a more favourable prognosis.[36] Copper’s ability to induce oxidative stress and DNA damage further contributes to the aggressive behavior of ovarian tumors.
Lead
Lead (Pb) is a non-essential and toxic heavy metal that has been implicated in the development of various cancers, including ovarian cancer. Chronic exposure to lead has been shown to induce oxidative stress, DNA damage, and epigenetic alterations. It has been identified as a metalloestrogen, meaning it can mimic estrogen and disrupt hormonal pathways, contributing to hormone-related cancers, including ovarian cancer.[37][38] Studies have shown that high lead concentrations in the blood are correlated with worse overall survival rates in ovarian cancer patients.[39][40]
Cadmium
Cadmium (Cd) is a carcinogenic heavy metal that has been linked to the onset of ovarian cancer, particularly through its genotoxic and endocrine-disrupting properties.[41] Cadmium can induce oxidative stress and impair the antioxidant defense system, leading to DNA damage and mutations. Like lead, cadmium is classified as a metalloestrogen and can interact with estrogen receptors, further contributing to the development of hormone-sensitive cancers, such as ovarian cancer.[42][43] Chronic exposure to cadmium has been associated with poor prognosis and increased resistance to chemotherapy.[44][45]
Metabolomic Signatures
Metabolomics has emerged as a promising approach for understanding the biochemical pathways involved in ovarian cancer. Metabolomic studies have identified specific metabolic changes that occur in ovarian cancer cells, which support rapid tumor growth and resistance to treatment.[46] These metabolic reprogramming features include alterations in glycolysis, lipid metabolism, and amino acid metabolism, which are critical for cancer cell survival.[47][48] For instance, the Warburg effect, which involves the shift from oxidative phosphorylation to glycolysis for ATP production, is frequently observed in ovarian cancer cells. This metabolic shift allows cancer cells to meet the increased energy demands required for rapid cell division.[49][50] Additionally, changes in lipid metabolism, such as increased synthesis of phospholipids, have been observed in ovarian cancer tissues. These alterations contribute to the structural integrity of cancer cell membranes and support cell proliferation.[51] Certain metabolites, such as N1,N12-diacetylspermine, polyamines, and betaine, have been consistently elevated in both plasma and ovarian cancer tissues, making them potential biomarkers for diagnosis and prognosis.[52][53] The identification of these metabolites through metabolomic profiling holds great promise for improving early detection and monitoring the progression of ovarian cancer.
Microbiome Signature: Ovarian Cancer
Interventions
Primary, first-line ovarian-cancer care still centers on maximal cytoreductive surgery (up-front or interval) coupled to platinum–taxane chemotherapy; despite this, recurrence after standard platinum regimens is common, which is why maintenance and targeted add-ons have become mainstream.[54][55] Bevacizumab (anti-VEGF) is an approved targeted agent in the frontline/maintenance setting.[56] Improved progression-free survival in large phase-III programs, as well as the pairing of olaparib with bevacizumab (PAOLA-1), boosted outcomes, especially in homologous recombination-deficient disease. Building on the backbone, drug repurposing is an active strategy: metformin exerts indirect anticancer effects by lowering insulin/IGF signaling and direct effects via complex-I inhibition with downstream AMPK activation, mTOR/PI3K restraint, and dampening ERK/STAT3, mechanisms that align with chemosensitization and anti-angiogenesis in preclinical ovarian models.[57] In vivo and in vitro work showed metformin suppressed adhesion, invasion, migration, and reduced neovascularization and macrophage infiltration in ovarian-cancer models, consistent with antimetastatic activity, while a 2024 population cohort found post-diagnosis metformin associated with improved survival in diabetics (aHR 0.71 for ovarian-cancer–specific mortality), encouraging, though not yet definitive for all comers.[58][59] Nutritional care is another pillar that directly affects tolerance and outcomes: up to 70% of women with ovarian cancer present malnourished and 40% have low muscle mass at diagnosis; early, individualized nutrition counseling (including in prehabilitation), oral nutrition support, and immunonutrition are feasible, reduce symptom burden, and may improve survival, an area urgently needing larger prospective trials but already important in practice.[60]
Microbiome-targeted interventions (MBTIs) for ovarian cancer
Multiple groups have confirmed that ovarian tumors, like several other cancers, harbor an intratumoral microbiome detectable by 16S/ITS profiling, with microbial signatures that may have diagnostic/prognostic value, while requiring rigorous contamination control.[61] In parallel, bacteria themselves are being developed as therapeutics: intratumoral or tumor-seeking microbes (or engineered strains) can deliver cytotoxics or immunomodulators directly in situ (e.g., anaerobes like Clostridium novyi-NT and engineered E. coli/Bifidobacterium platforms), illustrating a concrete path for “intratumoral microbiota therapy.”[62] Mechanistically, the ovarian-cancer–microbiome crosstalk appears to run through inflammation and metabolism: gut dysbiosis can raise systemic IL-6 and Other cytokines, activating JAK/STAT3 and NF-κB; in murine models, TLR5-responsive microbiota elevated IL-6 and accelerated ovarian tumor progression, whereas depleting symbionts abrogated the effect, linking microbial patterns to tumor-promoting inflammation.[63] On the protective side, commensals in the female tract and gut, Lactobacillus biofilms and lactic acid in the vagina, Clostridium spp., and Akkermansia muciniphila reinforce barriers and tune antitumor immunity.[64] Microbially derived short-chain fatty acids (SCFAs) can suppress inflammatory chemokines (e.g., CCL20, IL-8) within the tumor milieu.[65] Translationally, this opens four levers to correct dysbiosis and amplify antitumor immunity: (1) probiotics to restore barrier organisms and recalibrate cytokine tone. (2) microbiota supplementation via fecal microbiota transplant (FMT) or strain-level enrichment to ignite CD8⁺ T-cell activity and reverse tumor-promoting consortia.[66] (3) deliberate use of intratumoral/engineered bacteria as “living drugs.” (4) boosting SCFAs (by diet/prebiotics or direct postbiotics) to quiet NF-κB/STAT3-linked inflammation and enhance effector T-cell function. In ovarian-cancer models, adding Akkermansia through FMT increased CD8⁺ T-cell activity and flipped tumor behavior toward antitumor effects, supporting a rational, microbiome-targeted add-on to standard therapy.[67]
| Intervention | Mechanism | MBTI Status |
|---|---|---|
| Probiotics (e.g., Lactobacillus, Bifidobacterium, potentially A. muciniphila) | Rebuilds epithelial and mucosal barriers; Lactobacillus biofilms block pathogen adhesion and its lactic acid increases IL-1RA and suppresses TNF-α, reducing local inflammatory tone.[68] In the gut, commensals educate immunity—Clostridium spp. expand Tregs; A. muciniphila expands T-follicular helper cells—shifting the peritoneal/TME cytokine balance away from IL-6/STAT3 and toward more effective antigen handling.[69] SCFA output from these taxa further down-modulates chemokines (CCL20) and IL-8 in tumors. | Promising |
| Microbiota supplementation via FMT (with Akkermansia-enriched donors or strain add-back) | Replaces a tumor-promoting consortium with a community that favors antitumor immunity. In ovarian-cancer models, supplementing A. muciniphila via FMT activates CD8⁺ T cells and induces antitumor effects—likely via metabolic rewiring (glucose/AA flux) and dampening NF-κB/STAT3-linked cytokines.[70] Clinically, careful donor screening and standardized manufacturing are essential. | Under investigation |
| Intratumoral microbiota therapy (native or engineered bacteria delivered to, or homing in on, tumors) | Beneficial bacteria migrate/proliferate within tumors, rewiring glutamine/purine/pyrimidine metabolism; provide TLR agonism and metabolite delivery to ignite local immunity.[71] | Experimental |
| Increase SCFAs (dietary fiber/prebiotic strategies; targeted postbiotics) | Elevates butyrate/propionate/acetate at the gut-peritoneal axis. SCFAs act on epithelial and immune cells to suppress pro-inflammatory chemokines (e.g., CCL20) and IL-8 within tumors, helping to quell NF-κB/STAT3 signaling.[72] SCFAs also support effector T-cell metabolism and survival, aiding CD8⁺ function noted in preclinical ovarian systems.[73] Pairing with probiotics/synbiotics may synergize. | Promising |
| Repurposed Drugs |
| Metformin | Inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration of electrons transported by glucose deprivation, stopping Krebs cycle function.[74][75] Multiple observational cohorts & meta-analyses suggest improved survival in OC users; prospective trials ongoing. | Promising |
| Itraconazole (antifungal) | Hedgehog/angiogenesis inhibition; impacts cholesterol trafficking & mTOR; may enhance autophagy blockade with HCQ.[76][77] | Under investigation |
FAQs
What is intratumoral microbiota therapy in ovarian cancer?
What is intratumoral microbiota therapy in ovarian cancer?
Intratumoral microbiota therapy is an emerging and innovative approach that involves introducing beneficial bacteria directly into the tumor microenvironment (TME). The goal of this therapy is to manipulate the TME in ways that improve immune response, enhance the efficacy of cancer treatments, and potentially reverse the immunosuppressive effects within tumors. Certain beneficial bacteria, like Akkermansia muciniphila, have been shown to migrate from the gut to the primary tumor site and proliferate, where they can stimulate immune cells, such as CD8+ T cells, and enhance antitumor immunity. These bacteria help regulate tumor metabolism, such as glutamine and purine metabolism, creating an environment that is less conducive to cancer growth. By leveraging intratumoral microbiota, researchers aim to enhance cancer therapies like immunotherapy and chemotherapy, improving their ability to target and destroy cancer cells. This type of microbiome-targeted therapy is still in experimental stages, but it holds considerable promise for future treatments.
How does genetic testing help in ovarian cancer diagnosis and treatment?
How does genetic testing help in ovarian cancer diagnosis and treatment?
Genetic testing is an important tool in ovarian cancer diagnosis and treatment, particularly for identifying inherited mutations like BRCA1 and BRCA2. These genes play a key role in DNA repair, and mutations can significantly increase the risk of developing ovarian cancer. Genetic testing helps determine if a patient has inherited these mutations, which can influence treatment decisions, such as the use of PARP inhibitors (e.g., olaparib, rucaparib), which are especially effective in patients with BRCA mutations. Additionally, genetic testing can help assess other mutations related to Lynch syndrome, which also increases ovarian cancer risk. For patients without a family history, testing can guide personalized treatment approaches, including the potential for clinical trials and specific drug regimens, thus improving outcomes.
Can hormonal therapy be used to treat ovarian cancer?
Can hormonal therapy be used to treat ovarian cancer?
Hormonal therapy is not typically the first-line treatment for ovarian cancer but may be used in certain cases, particularly for hormone-sensitive subtypes of the disease, such as low-grade serous carcinoma or endometrioid ovarian cancer. These types of ovarian cancer express hormone receptors, and treatments that block estrogen or progesterone can help slow cancer growth. Medications like tamoxifen, which blocks estrogen receptors, or aromatase inhibitors, which reduce estrogen production, are sometimes used in these cases, especially in patients who have already undergone surgery and chemotherapy. However, hormonal therapy is generally more effective for certain subtypes and is usually considered for recurrent or advanced disease.
Research Feed
Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence
October 19, 2023
/
Metals •
Metals
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin ut laoreet tortor. Donec euismod fermentum pharetra. Nullam at tristique enim. In sit amet molestie
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The Role of Lead and Cadmium in Gynecological Malignancies
December 15, 2022
/
Metals •
Metals
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin ut laoreet tortor. Donec euismod fermentum pharetra. Nullam at tristique enim. In sit amet molestie
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Breast Cancer •
Breast Cancer
Did You Know?
The Left Breast Is Slightly More Susceptible. Breast cancer is about 5–10% more common in the left breast than the right. Researchers are still exploring why this asymmetry exists.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Urinary heavy metals and overall survival of advanced high-grade serous ovarian cancer: A nested case-control study in China
October 15, 2024
/
Metals •
Metals
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin ut laoreet tortor. Donec euismod fermentum pharetra. Nullam at tristique enim. In sit amet molestie
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Extended sub-chronic exposure to heavy metal mixture induced multidrug resistance against chemotherapy agents in ovarian cancer cells
March 28, 2025
/
Metals •
Metals
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin ut laoreet tortor. Donec euismod fermentum pharetra. Nullam at tristique enim. In sit amet molestie
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The Role of Heavy Metals in the Biology of Female Cancers
May 28, 2025
/
Metals •
Metals
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin ut laoreet tortor. Donec euismod fermentum pharetra. Nullam at tristique enim. In sit amet molestie
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study
January 23, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Causal association between 637 human metabolites and ovarian cancer: A mendelian randomization study
January 23, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids
September 16, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The application of metabolomics in ovarian cancer management: A systematic review
October 26, 2020
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review
March 21, 2024
/
Microbes •
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Nutritional interventions during treatment for ovarian cancer: A narrative review and recommendations for future research
February 10, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—A narrative review
June 14, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
January 14, 2025
/
Drug Repurposing •
Drug Repurposing
By capitalizing on the wealth of existing pharmacological knowledge and embracing new scientific methodologies, drug repurposing holds tremendous promise for accelerating the development of effective, accessible, and affordable treatments for a wide range of diseases.
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer
October 20, 2020
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Drug Repurposing •
Drug Repurposing
By capitalizing on the wealth of existing pharmacological knowledge and embracing new scientific methodologies, drug repurposing holds tremendous promise for accelerating the development of effective, accessible, and affordable treatments for a wide range of diseases.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects
September 14, 2023
/
Drug Repurposing •
Drug Repurposing
By capitalizing on the wealth of existing pharmacological knowledge and embracing new scientific methodologies, drug repurposing holds tremendous promise for accelerating the development of effective, accessible, and affordable treatments for a wide range of diseases.
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada
July 6, 2024
/
Drug Repurposing •
Drug Repurposing
By capitalizing on the wealth of existing pharmacological knowledge and embracing new scientific methodologies, drug repurposing holds tremendous promise for accelerating the development of effective, accessible, and affordable treatments for a wide range of diseases.
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance
April 13, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Endometriosis •
Endometriosis
Did you know?
Gut microbiota predict endometriosis better than vaginal microbiota.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Endometriosis and Ovarian Cancer: An Integrative Review (Endometriosis and Ovarian Cancer)
January 1, 2017
/
Endometriosis •
Endometriosis
Did you know?
Gut microbiota predict endometriosis better than vaginal microbiota.
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer
August 2, 2025
/
Microbes •
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling
April 1, 2021
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The microbiome and ovarian cancer: insights, implications, and therapeutic opportunities
November 23, 2023
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The Gut Microbiome in Aging and Ovarian Cancer
June 20, 2024
/
Microbes •
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment
March 15, 2023
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Dietary Intake and Ovarian Cancer Risk: A Systematic Review
February 4, 2014
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Diet and ovarian cancer risk: A case–control study in China
February 26, 2002
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Diet-driven microbiome changes and physical activity in cancer patients
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Probiotics as Anti-Tumor Agents: Insights from Female Tumor Cell Culture Studies
May 2, 2025
/
Microbes •
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Breast Cancer •
Breast Cancer
Did You Know?
The Left Breast Is Slightly More Susceptible. Breast cancer is about 5–10% more common in the left breast than the right. Researchers are still exploring why this asymmetry exists.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.
February 3, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Ovarian cancer in the world: Epidemiology and risk factors
April 30, 2019
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Ovarian cancer: Diagnosis and treatment strategies (Review)
July 18, 2024
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds
May 12, 2025
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers
March 4, 2020
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis
October 1, 2015
/
Ovarian Cancer •
Ovarian Cancer
Did you know?
Ovarian cancer is known as the “silent killer” because it often shows no symptoms until it has reached advanced stages. Many of the symptoms, such as bloating, pelvic pain, and urinary frequency, are common to other, less serious conditions, which makes early detection difficult. As a result, over 70% of ovarian cancer cases are diagnosed in later stages when treatment options are more limited, leading to a lower survival rate.
Alias iure reprehenderit aut accusantium. Molestiae dolore suscipit. Necessitatibus eum quaerat. Repudiandae suscipit quo necessitatibus. Voluptatibus ullam nulla temporibus nobis. Atque eaque sed totam est assumenda. Porro modi soluta consequuntur veritatis excepturi minus delectus reprehenderit est. Eveniet labore ut quas minima aliquid quibusdam. Vitae possimus fuga praesentium eveniet debitis exercitationem deleniti.
Create a free account to unlock this study summary.
Microbiome Insiders can read two study summaries for any topic on Microbiome.
Update History
Metalloestrogens
Metalloestrogens are metals that activate the estrogen receptor in the absence of estradiol.
Metformin
Metformin is a synthetic derivative of guanidine derived from the guanidine alkaloid of the plant Galega officinalis L. with significant hypoglycemic effects. It is a first-line antihyperglycemic agent due to its efficacy, low cost, and favorable safety profile.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Breast Cancer
Traditionally linked to genetic predispositions and environmental exposures, emerging evidence highlights the microbiome as a critical and underappreciated factor influencing breast cancer progression, immune response, and treatment outcomes.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Drug Repurposing
Drug repurposing involves identifying new therapeutic uses for existing drugs, offering a cost-effective and time-efficient pathway to enhance treatment options and address unmet medical needs.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Drug Repurposing
Drug repurposing involves identifying new therapeutic uses for existing drugs, offering a cost-effective and time-efficient pathway to enhance treatment options and address unmet medical needs.
Drug Repurposing
Drug repurposing involves identifying new therapeutic uses for existing drugs, offering a cost-effective and time-efficient pathway to enhance treatment options and address unmet medical needs.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Drug Repurposing
Drug repurposing involves identifying new therapeutic uses for existing drugs, offering a cost-effective and time-efficient pathway to enhance treatment options and address unmet medical needs.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Endometriosis
Endometriosis involves ectopic endometrial tissue causing pain and infertility. Validated and Promising Interventions include Hyperbaric Oxygen Therapy (HBOT), Low Nickel Diet, and Metronidazole therapy.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Endometriosis
Endometriosis involves ectopic endometrial tissue causing pain and infertility. Validated and Promising Interventions include Hyperbaric Oxygen Therapy (HBOT), Low Nickel Diet, and Metronidazole therapy.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Breast Cancer
Traditionally linked to genetic predispositions and environmental exposures, emerging evidence highlights the microbiome as a critical and underappreciated factor influencing breast cancer progression, immune response, and treatment outcomes.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
Women’s Health
Women’s health, a vital aspect of medical science, encompasses various conditions unique to women’s physiological makeup. Historically, women were often excluded from clinical research, leading to a gap in understanding the intricacies of women’s health needs. However, recent advancements have highlighted the significant role that the microbiome plays in these conditions, offering new insights and potential therapies. MicrobiomeSignatures.com is at the forefront of exploring the microbiome signature of each of these conditions to unravel the etiology of these diseases and develop targeted microbiome therapies.
Ovarian Cancer
Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its "silent" progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.
References
- Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers.. Trinidad, C. V., Tetlow, A. L., Bantis, L. E., & Godwin, A. K. (2020).. (Cancer Prevention Research (Philadelphia, Pa.), 13(3), 241.)
- Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.. Yeung, L., Leung, C. S., Yip, P., Au Yeung, C. L., C. Wong, S. T., & Mok, S. C. (2015).. (American Journal of Physiology-Cell Physiology.)
- Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.. Yeung, L., Leung, C. S., Yip, P., Au Yeung, C. L., C. Wong, S. T., & Mok, S. C. (2015).. (American Journal of Physiology-Cell Physiology.)
- Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers.. Trinidad, C. V., Tetlow, A. L., Bantis, L. E., & Godwin, A. K. (2020).. (Cancer Prevention Research (Philadelphia, Pa.), 13(3), 241.)
- Ovarian cancer in the world: Epidemiology and risk factors.. Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019).. (International Journal of Women’s Health, 11, 287.)
- The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.. Chalif, J., Wang, H., Spakowicz, D., Quick, A., Arthur, E. K., O’Malley, D., & Chambers, L. M. (2024).. (International Journal of Gynecological Cancer, 34(2), 317-327.)
- The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer.. AlHilli, M.M., Sangwan, N., Myers, A. et al.. (J Ovarian Res 18, 174 (2025).)
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.. Mohi-ud-din, R., Chawla, A., Sharma, P. et al.. (Eur J Med Res 28, 345 (2023).)
- Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.. Steinbuch, S. C., Lüß, A., Eltrop, S., Götte, M., & Kiesel, L. (2023).. (International Journal of Molecular Sciences, 25(8), 4306.)
- Endometriosis and Ovarian Cancer: An Integrative Review (Endometriosis and Ovarian Cancer).. Morais Brilhante, A. V., Augusto, K. L., Portela, M. C., Gabriele Sucupira, L. C., Freitas Oliveira, L. A., Magalhães Veríssimo Pouchaim, A. J., Mesquita Nóbrega, L. R., & Pinheiro Sobreira, L. R. (2017).. (Asian Pacific Journal of Cancer Prevention : APJCP, 18(1), 11.)
- Endometriosis Typology and Ovarian Cancer Risk.. Barnard, M. E., Farland, L. V., Yan, B., Wang, J., Trabert, B., Doherty, J. A., Meeks, H. D., Madsen, M., Guinto, E., Collin, L. J., Maurer, K. A., Page, J. M., Kiser, A. C., Varner, M. W., Allen-Brady, K., Pollack, A. Z., Peterson, K. R., Peterson, C. M., & Schliep, K. C. (2024).. (JAMA, 332(6), 482.)
- Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.. Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).. (International Journal of Molecular Sciences, 26(10), 4611.)
- Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.. Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).. (International Journal of Molecular Sciences, 26(10), 4611.)
- Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.. Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).. (International Journal of Molecular Sciences, 26(10), 4611.)
- The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis.. Xiang, H., Wang, L., Sun, L., & Xu, S. (2024). The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis. Frontiers in Endocrinology, 15, 1414968.. (Frontiers in Endocrinology, 15, 1414968.)
- Circulating estrogens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study.. Trabert, B., Brinton, L. A., Anderson, G. L., Pfeiffer, R. M., Falk, R. T., Strickler, H. D., Sliesoraitis, S., Kuller, L. H., Gass, M. L., Fuhrman, B. J., Xu, X., & Wentzensen, N. (2016).. (Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 25(4), 648.)
- Lifetime ovulatory years and ovarian cancer gene expression profiles.. Sasamoto, N., Stewart, P.A., Wang, T. et al.. (J Ovarian Res 15, 59 (2022).)
- Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.. Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).. (International Journal of Molecular Sciences, 26(10), 4611.)
- The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer.. AlHilli, M.M., Sangwan, N., Myers, A. et al.. (J Ovarian Res 18, 174 (2025).)
- The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease.. Trifanescu, O. G., Trifanescu, R. A., Mitrica, R. I., Bran, D. M., Serbanescu, G. L., Valcauan, L., Marinescu, S. A., Gales, L. N., Tanase, B. C., & Anghel, R. M. (2022).. (Diagnostics, 13(5), 877.)
- Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.. Choi, S., & Choi, J. (2024).. (Medicina, 60(3), 516.)
- The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.. Chalif, J., Wang, H., Spakowicz, D., Quick, A., Arthur, E. K., O’Malley, D., & Chambers, L. M. (2024).. (International Journal of Gynecological Cancer, 34(2), 317-327.)
- The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis.. Xiang, H., Wang, L., Sun, L., & Xu, S. (2024). The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis. Frontiers in Endocrinology, 15, 1414968.. (Frontiers in Endocrinology, 15, 1414968.)
- Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.. Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).. (International Journal of Molecular Sciences, 26(10), 4611.)
- Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.. Choi, S., & Choi, J. (2024).. (Medicina, 60(3), 516.)
- Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers.. Trinidad, C. V., Tetlow, A. L., Bantis, L. E., & Godwin, A. K. (2020).. (Cancer Prevention Research (Philadelphia, Pa.), 13(3), 241.)
- Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.. Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).. (International Journal of Molecular Sciences, 26(10), 4611.)
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.. Tavares, V., Marques, I. S., Assis, J., Pereira, D., & Medeiros, R. (2024).. (International Journal of Molecular Sciences, 25(3), 1845.)
- Ovarian cancer: Diagnosis and treatment strategies (Review).. Li, X., Li, Z., Ma, H., Li, X., Zhai, H., Li, X. … Hao, Z. (2024).. (Oncology Letters, 28, 441.)
- Ovarian cancer: Diagnosis and treatment strategies (Review).. Li, X., Li, Z., Ma, H., Li, X., Zhai, H., Li, X. … Hao, Z. (2024).. (Oncology Letters, 28, 441.)
- The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.. Chalif, J., Wang, H., Spakowicz, D., Quick, A., Arthur, E. K., O’Malley, D., & Chambers, L. M. (2024).. (International Journal of Gynecological Cancer, 34(2), 317-327.)
- Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence.. Drin, Ivan & Kryzhanivska, Anna. (2023).. (Archive of Clinical Medicine. 29. 4-8.)
- Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence.. Drin, Ivan & Kryzhanivska, Anna. (2023).. (Archive of Clinical Medicine. 29. 4-8.)
- Cellular Mechanisms of Zinc Dysregulation: A Perspective on Zinc Homeostasis as an Etiological Factor in the Development and Progression of Breast Cancer.. Alam, S., & Kelleher, S. L. (2012).. (Nutrients, 4(8), 875.)
- Copper in cancer: Friend or foe? Metabolism, dysregulation, and therapeutic opportunities.. Shan, D., Song, J., Ren, Y., Zhang, Y., Ba, Y., Luo, P., Cheng, Q., Xu, H., Weng, S., Zuo, A., Liu, S., Han, X., Deng, J., & Liu, Z. (2025).. (Cancer Communications, 45(5), 577.)
- Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence.. Drin, Ivan & Kryzhanivska, Anna. (2023).. (Archive of Clinical Medicine. 29. 4-8.)
- The Role of Lead and Cadmium in Gynecological Malignancies.. Furtak, G., Kozłowski, M., Kwiatkowski, S., & Cymbaluk-Płoska, A. (2022).. (Antioxidants, 11(12), 2468.)
- The Role of Heavy Metals in the Biology of Female Cancers.. Kozak J.. (International Journal of Molecular Sciences. 2025; 26(11):5155.)
- Extended sub-chronic exposure to heavy metal mixture induced multidrug resistance against chemotherapy agents in ovarian cancer cells.. Sahin, G., & Doğanlar, Z. B. (2025).. (Toxicology Letters, 407, 50-62.)
- Urinary heavy metals and overall survival of advanced high-grade serous ovarian cancer: A nested case-control study in China.. Liu, J., Liu, F., Qin, X., Bao, Q., Zheng, W., Xing, W., Wu, L., Li, Y., Xu, H., Wei, Y., Li, X., Huang, D., Gao, S., Wang, L., Ma, Q., Gong, T., & Wu, Q. (2024).. (Ecotoxicology and Environmental Safety, 286, 117176.)
- Cadmium as an ovarian toxicant: A review.. Bhardwaj, Jitender & Bikal, Prerna & Sachdeva, Som Nath. (2023).. (Journal of applied toxicology : JAT. 44.)
- The Role of Lead and Cadmium in Gynecological Malignancies.. Furtak, G., Kozłowski, M., Kwiatkowski, S., & Cymbaluk-Płoska, A. (2022).. (Antioxidants, 11(12), 2468.)
- The Role of Heavy Metals in the Biology of Female Cancers.. Kozak J.. (International Journal of Molecular Sciences. 2025; 26(11):5155.)
- Extended sub-chronic exposure to heavy metal mixture induced multidrug resistance against chemotherapy agents in ovarian cancer cells.. Sahin, G., & Doğanlar, Z. B. (2025).. (Toxicology Letters, 407, 50-62.)
- Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma.. Venza, M., Visalli, M., Biondo, C., Oteri, R., Agliano, F., Morabito, S., Caruso, G., Caffo, M., Teti, D., & Venza, I. (2014).. (Current Genomics, 15(6), 420.)
- Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study.. Liu, S., Ding, D., Liu, F. et al.. (J Ovarian Res 17, 22 (2024).)
- Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study.. Liu, S., Ding, D., Liu, F. et al.. (J Ovarian Res 17, 22 (2024).)
- Causal association between 637 human metabolites and ovarian cancer: A mendelian randomization study.. Huang, Y., Lin, W., & Zheng, X. (2024).. (BMC Genomics, 25, 97.)
- The application of metabolomics in ovarian cancer management: A systematic review.. Ahmed-Salim, Y., Galazis, N., Bracewell-Milnes, T., Phelps, D. L., Jones, B. P., Chan, M., Munoz-Gonzales, M. D., Matsuzono, T., Smith, J. R., Yazbek, J., Krell, J., Ghaem-Maghami, S., & Saso, S. (2021).. (International Journal of Gynecological Cancer, 31(5), 754-774.)
- Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids.. Ohta, T., Sugimoto, M., Ito, Y., Horikawa, S., Okui, Y., Sakaki, H., Seino, M., Sunamura, M., & Nagase, S. (2024).. (Scientific Reports, 14(1), 1-11.)
- The application of metabolomics in ovarian cancer management: A systematic review.. Ahmed-Salim, Y., Galazis, N., Bracewell-Milnes, T., Phelps, D. L., Jones, B. P., Chan, M., Munoz-Gonzales, M. D., Matsuzono, T., Smith, J. R., Yazbek, J., Krell, J., Ghaem-Maghami, S., & Saso, S. (2021).. (International Journal of Gynecological Cancer, 31(5), 754-774.)
- Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids.. Ohta, T., Sugimoto, M., Ito, Y., Horikawa, S., Okui, Y., Sakaki, H., Seino, M., Sunamura, M., & Nagase, S. (2024).. (Scientific Reports, 14(1), 1-11.)
- Causal association between 637 human metabolites and ovarian cancer: A mendelian randomization study.. Huang, Y., Lin, W., & Zheng, X. (2024).. (BMC Genomics, 25, 97.)
- New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—A narrative review.. Satora, M., Kułak, K., Zaremba, B., Grunwald, A., & Tarkowski, R. (2024).. (Frontiers in Pharmacology, 15, 1416555.)
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.. Yebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).. (Frontiers in Oncology, 14, 1514120.)
- New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—A narrative review.. Satora, M., Kułak, K., Zaremba, B., Grunwald, A., & Tarkowski, R. (2024).. (Frontiers in Pharmacology, 15, 1416555.)
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.. Yebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).. (Frontiers in Oncology, 14, 1514120.)
- Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.. Kaur, P., Berchuck, A., Chase, A., Grout, B., Deurloo, C. M., Pearce, L. C., Pike, M. C., Richardson, J., Terry, K. L., Webb, P. M., & Hanley, G. E. (2024).. (Neoplasia, 56, 101026.)
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.. Yebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).. (Frontiers in Oncology, 14, 1514120.)
- Nutritional interventions during treatment for ovarian cancer: A narrative review and recommendations for future research.. Benna-Doyle, S., Baguley, B. J., Laing, E., & Kiss, N. (2024).. (Maturitas, 183, 107938.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.. Choi, S., & Choi, J. (2024).. (Medicina, 60(3), 516.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.. Choi, S., & Choi, J. (2024).. (Medicina, 60(3), 516.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.. Zhang, M., Mo, J., Huang, W., & Bao, Y. (2024).. (Frontiers in Cellular and Infection Microbiology, 14, 1440742.)
- Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.. Choi, S., & Choi, J. (2024).. (Medicina, 60(3), 516.)
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.. Yebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).. (Frontiers in Oncology, 14, 1514120.)
- Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.. Nunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. (2020).. (International Journal of Molecular Sciences, 21(20), 7768.)
- Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.. Nunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. (2020).. (International Journal of Molecular Sciences, 21(20), 7768.)
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.. Mohi-ud-din, R., Chawla, A., Sharma, P. et al.. (Eur J Med Res 28, 345 (2023).)
Trinidad, C. V., Tetlow, A. L., Bantis, L. E., & Godwin, A. K. (2020).
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers.Cancer Prevention Research (Philadelphia, Pa.), 13(3), 241.
Read ReviewYeung, L., Leung, C. S., Yip, P., Au Yeung, C. L., C. Wong, S. T., & Mok, S. C. (2015).
Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.American Journal of Physiology-Cell Physiology.
Read ReviewYeung, L., Leung, C. S., Yip, P., Au Yeung, C. L., C. Wong, S. T., & Mok, S. C. (2015).
Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.American Journal of Physiology-Cell Physiology.
Read ReviewTrinidad, C. V., Tetlow, A. L., Bantis, L. E., & Godwin, A. K. (2020).
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers.Cancer Prevention Research (Philadelphia, Pa.), 13(3), 241.
Read ReviewMomenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019).
Ovarian cancer in the world: Epidemiology and risk factors.International Journal of Women’s Health, 11, 287.
Read ReviewChalif, J., Wang, H., Spakowicz, D., Quick, A., Arthur, E. K., O’Malley, D., & Chambers, L. M. (2024).
The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.International Journal of Gynecological Cancer, 34(2), 317-327.
Read ReviewAlHilli, M.M., Sangwan, N., Myers, A. et al.
The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer.J Ovarian Res 18, 174 (2025).
Read ReviewMohi-ud-din, R., Chawla, A., Sharma, P. et al.
Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.Eur J Med Res 28, 345 (2023).
Read ReviewSteinbuch, S. C., Lüß, A., Eltrop, S., Götte, M., & Kiesel, L. (2023).
Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.International Journal of Molecular Sciences, 25(8), 4306.
Read ReviewMorais Brilhante, A. V., Augusto, K. L., Portela, M. C., Gabriele Sucupira, L. C., Freitas Oliveira, L. A., Magalhães Veríssimo Pouchaim, A. J., Mesquita Nóbrega, L. R., & Pinheiro Sobreira, L. R. (2017).
Endometriosis and Ovarian Cancer: An Integrative Review (Endometriosis and Ovarian Cancer).Asian Pacific Journal of Cancer Prevention : APJCP, 18(1), 11.
Read ReviewBarnard, M. E., Farland, L. V., Yan, B., Wang, J., Trabert, B., Doherty, J. A., Meeks, H. D., Madsen, M., Guinto, E., Collin, L. J., Maurer, K. A., Page, J. M., Kiser, A. C., Varner, M. W., Allen-Brady, K., Pollack, A. Z., Peterson, K. R., Peterson, C. M., & Schliep, K. C. (2024).
Endometriosis Typology and Ovarian Cancer Risk.JAMA, 332(6), 482.
Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.International Journal of Molecular Sciences, 26(10), 4611.
Read ReviewSmolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.International Journal of Molecular Sciences, 26(10), 4611.
Read ReviewSmolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.International Journal of Molecular Sciences, 26(10), 4611.
Read ReviewXiang, H., Wang, L., Sun, L., & Xu, S. (2024). The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis. Frontiers in Endocrinology, 15, 1414968.
The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis.Frontiers in Endocrinology, 15, 1414968.
Trabert, B., Brinton, L. A., Anderson, G. L., Pfeiffer, R. M., Falk, R. T., Strickler, H. D., Sliesoraitis, S., Kuller, L. H., Gass, M. L., Fuhrman, B. J., Xu, X., & Wentzensen, N. (2016).
Circulating estrogens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study.Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 25(4), 648.
Sasamoto, N., Stewart, P.A., Wang, T. et al.
Lifetime ovulatory years and ovarian cancer gene expression profiles.J Ovarian Res 15, 59 (2022).
Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.International Journal of Molecular Sciences, 26(10), 4611.
Read ReviewAlHilli, M.M., Sangwan, N., Myers, A. et al.
The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer.J Ovarian Res 18, 174 (2025).
Read ReviewTrifanescu, O. G., Trifanescu, R. A., Mitrica, R. I., Bran, D. M., Serbanescu, G. L., Valcauan, L., Marinescu, S. A., Gales, L. N., Tanase, B. C., & Anghel, R. M. (2022).
The Female Reproductive Tract Microbiome and Cancerogenesis: A Review Story of Bacteria, Hormones, and Disease.Diagnostics, 13(5), 877.
Read ReviewChoi, S., & Choi, J. (2024).
Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.Medicina, 60(3), 516.
Read ReviewChalif, J., Wang, H., Spakowicz, D., Quick, A., Arthur, E. K., O’Malley, D., & Chambers, L. M. (2024).
The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.International Journal of Gynecological Cancer, 34(2), 317-327.
Read ReviewXiang, H., Wang, L., Sun, L., & Xu, S. (2024). The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis. Frontiers in Endocrinology, 15, 1414968.
The risk of ovarian cancer in hormone replacement therapy users: A systematic review and meta-analysis.Frontiers in Endocrinology, 15, 1414968.
Smolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.International Journal of Molecular Sciences, 26(10), 4611.
Read ReviewChoi, S., & Choi, J. (2024).
Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.Medicina, 60(3), 516.
Read ReviewTrinidad, C. V., Tetlow, A. L., Bantis, L. E., & Godwin, A. K. (2020).
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches using Circulating Biomarkers.Cancer Prevention Research (Philadelphia, Pa.), 13(3), 241.
Read ReviewSmolarz, B., Biernacka, K., Łukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., & Makowska, M. (2024).
Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds.International Journal of Molecular Sciences, 26(10), 4611.
Read ReviewTavares, V., Marques, I. S., Assis, J., Pereira, D., & Medeiros, R. (2024).
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.International Journal of Molecular Sciences, 25(3), 1845.
Read ReviewLi, X., Li, Z., Ma, H., Li, X., Zhai, H., Li, X. … Hao, Z. (2024).
Ovarian cancer: Diagnosis and treatment strategies (Review).Oncology Letters, 28, 441.
Read ReviewLi, X., Li, Z., Ma, H., Li, X., Zhai, H., Li, X. … Hao, Z. (2024).
Ovarian cancer: Diagnosis and treatment strategies (Review).Oncology Letters, 28, 441.
Read ReviewChalif, J., Wang, H., Spakowicz, D., Quick, A., Arthur, E. K., O’Malley, D., & Chambers, L. M. (2024).
The microbiome and gynecologic cancer: Cellular mechanisms and clinical applications.International Journal of Gynecological Cancer, 34(2), 317-327.
Read ReviewDrin, Ivan & Kryzhanivska, Anna. (2023).
Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence.Archive of Clinical Medicine. 29. 4-8.
Read ReviewDrin, Ivan & Kryzhanivska, Anna. (2023).
Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence.Archive of Clinical Medicine. 29. 4-8.
Read ReviewAlam, S., & Kelleher, S. L. (2012).
Cellular Mechanisms of Zinc Dysregulation: A Perspective on Zinc Homeostasis as an Etiological Factor in the Development and Progression of Breast Cancer.Nutrients, 4(8), 875.
Shan, D., Song, J., Ren, Y., Zhang, Y., Ba, Y., Luo, P., Cheng, Q., Xu, H., Weng, S., Zuo, A., Liu, S., Han, X., Deng, J., & Liu, Z. (2025).
Copper in cancer: Friend or foe? Metabolism, dysregulation, and therapeutic opportunities.Cancer Communications, 45(5), 577.
Drin, Ivan & Kryzhanivska, Anna. (2023).
Correlation of Heavy Metal Content in the Blood of Patients with Ovarian Cancer by Place of Residence.Archive of Clinical Medicine. 29. 4-8.
Read ReviewFurtak, G., Kozłowski, M., Kwiatkowski, S., & Cymbaluk-Płoska, A. (2022).
The Role of Lead and Cadmium in Gynecological Malignancies.Antioxidants, 11(12), 2468.
Read ReviewKozak J.
The Role of Heavy Metals in the Biology of Female Cancers.International Journal of Molecular Sciences. 2025; 26(11):5155.
Read ReviewSahin, G., & Doğanlar, Z. B. (2025).
Extended sub-chronic exposure to heavy metal mixture induced multidrug resistance against chemotherapy agents in ovarian cancer cells.Toxicology Letters, 407, 50-62.
Read ReviewLiu, J., Liu, F., Qin, X., Bao, Q., Zheng, W., Xing, W., Wu, L., Li, Y., Xu, H., Wei, Y., Li, X., Huang, D., Gao, S., Wang, L., Ma, Q., Gong, T., & Wu, Q. (2024).
Urinary heavy metals and overall survival of advanced high-grade serous ovarian cancer: A nested case-control study in China.Ecotoxicology and Environmental Safety, 286, 117176.
Read ReviewBhardwaj, Jitender & Bikal, Prerna & Sachdeva, Som Nath. (2023).
Cadmium as an ovarian toxicant: A review.Journal of applied toxicology : JAT. 44.
Furtak, G., Kozłowski, M., Kwiatkowski, S., & Cymbaluk-Płoska, A. (2022).
The Role of Lead and Cadmium in Gynecological Malignancies.Antioxidants, 11(12), 2468.
Read ReviewKozak J.
The Role of Heavy Metals in the Biology of Female Cancers.International Journal of Molecular Sciences. 2025; 26(11):5155.
Read ReviewSahin, G., & Doğanlar, Z. B. (2025).
Extended sub-chronic exposure to heavy metal mixture induced multidrug resistance against chemotherapy agents in ovarian cancer cells.Toxicology Letters, 407, 50-62.
Read ReviewVenza, M., Visalli, M., Biondo, C., Oteri, R., Agliano, F., Morabito, S., Caruso, G., Caffo, M., Teti, D., & Venza, I. (2014).
Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma.Current Genomics, 15(6), 420.
Liu, S., Ding, D., Liu, F. et al.
Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study.J Ovarian Res 17, 22 (2024).
Read ReviewLiu, S., Ding, D., Liu, F. et al.
Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study.J Ovarian Res 17, 22 (2024).
Read ReviewHuang, Y., Lin, W., & Zheng, X. (2024).
Causal association between 637 human metabolites and ovarian cancer: A mendelian randomization study.BMC Genomics, 25, 97.
Read ReviewAhmed-Salim, Y., Galazis, N., Bracewell-Milnes, T., Phelps, D. L., Jones, B. P., Chan, M., Munoz-Gonzales, M. D., Matsuzono, T., Smith, J. R., Yazbek, J., Krell, J., Ghaem-Maghami, S., & Saso, S. (2021).
The application of metabolomics in ovarian cancer management: A systematic review.International Journal of Gynecological Cancer, 31(5), 754-774.
Read ReviewOhta, T., Sugimoto, M., Ito, Y., Horikawa, S., Okui, Y., Sakaki, H., Seino, M., Sunamura, M., & Nagase, S. (2024).
Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids.Scientific Reports, 14(1), 1-11.
Read ReviewAhmed-Salim, Y., Galazis, N., Bracewell-Milnes, T., Phelps, D. L., Jones, B. P., Chan, M., Munoz-Gonzales, M. D., Matsuzono, T., Smith, J. R., Yazbek, J., Krell, J., Ghaem-Maghami, S., & Saso, S. (2021).
The application of metabolomics in ovarian cancer management: A systematic review.International Journal of Gynecological Cancer, 31(5), 754-774.
Read ReviewOhta, T., Sugimoto, M., Ito, Y., Horikawa, S., Okui, Y., Sakaki, H., Seino, M., Sunamura, M., & Nagase, S. (2024).
Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids.Scientific Reports, 14(1), 1-11.
Read ReviewHuang, Y., Lin, W., & Zheng, X. (2024).
Causal association between 637 human metabolites and ovarian cancer: A mendelian randomization study.BMC Genomics, 25, 97.
Read ReviewSatora, M., Kułak, K., Zaremba, B., Grunwald, A., & Tarkowski, R. (2024).
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—A narrative review.Frontiers in Pharmacology, 15, 1416555.
Read ReviewYebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in Oncology, 14, 1514120.
Read ReviewSatora, M., Kułak, K., Zaremba, B., Grunwald, A., & Tarkowski, R. (2024).
New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—A narrative review.Frontiers in Pharmacology, 15, 1416555.
Read ReviewYebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in Oncology, 14, 1514120.
Read ReviewKaur, P., Berchuck, A., Chase, A., Grout, B., Deurloo, C. M., Pearce, L. C., Pike, M. C., Richardson, J., Terry, K. L., Webb, P. M., & Hanley, G. E. (2024).
Metformin use and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.Neoplasia, 56, 101026.
Read ReviewYebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in Oncology, 14, 1514120.
Read ReviewBenna-Doyle, S., Baguley, B. J., Laing, E., & Kiss, N. (2024).
Nutritional interventions during treatment for ovarian cancer: A narrative review and recommendations for future research.Maturitas, 183, 107938.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewChoi, S., & Choi, J. (2024).
Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.Medicina, 60(3), 516.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewChoi, S., & Choi, J. (2024).
Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.Medicina, 60(3), 516.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewZhang, M., Mo, J., Huang, W., & Bao, Y. (2024).
The ovarian cancer-associated microbiome contributes to the tumor’s inflammatory microenvironment.Frontiers in Cellular and Infection Microbiology, 14, 1440742.
Read ReviewChoi, S., & Choi, J. (2024).
Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations—A Review.Medicina, 60(3), 516.
Read ReviewYebran, E., Pável, F., Daniel, O., S., A., Patricia, L., & Itzel, L. (2025).
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in Oncology, 14, 1514120.
Read ReviewNunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. (2020).
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.International Journal of Molecular Sciences, 21(20), 7768.
Read ReviewNunes, M., Abreu, M. H., Bartosch, C., & Ricardo, S. (2020).
Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.International Journal of Molecular Sciences, 21(20), 7768.
Read ReviewMohi-ud-din, R., Chawla, A., Sharma, P. et al.
Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.Eur J Med Res 28, 345 (2023).
Read Review